Login to Your Account



Pharma: Clinic Roundup


Friday, July 12, 2013
• Ipsen SA, of Paris, reported results from the primary endpoint of the CLARINET study, which is testing the effect of Somatuline Autogel 120 mg on tumor progression-free survival in patients with gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs), showing that treatment with Somatuline was found to be statistically significantly superior to placebo in extending time to either disease progression or death.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription